Evidence map›Paper›PMID 34543354›Full record

ArticlePloS one2021

Automated monitoring of respiratory rate as a novel humane endpoint: A refinement in mouse metastatic lung cancer models.

Caroline B Winn, Seo-Kyoung Hwang, Jeffrey Morin, Crystal T Bluette, Balasubramanian Manickam, Ziyue K Jiang, Anand Giddabasappa, Chang-Ning Liu, Kristin Matthews

Abstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Disease Animal Models for Cancer Research.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Caroline B WinnComparative Medicine, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, United States of America.
Seo-Kyoung HwangComparative Medicine, Pfizer Worldwide Research, Development & Medical, Groton, Connecticut, United States of America.ORCID 0000-0003-0866-5376
Jeffrey MorinComparative Medicine, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, United States of America.
Crystal T BluetteComparative Medicine, Pfizer Worldwide Research, Development & Medical, Cambridge, Massachusetts, United States of America.
Balasubramanian ManickamGlobal Pathology and Investigative Toxicology, Pfizer Worldwide Research, Development & Medical, Groton, Connecticut, United States of America.
Ziyue K JiangComparative Medicine, Pfizer Worldwide Research, Development & Medical, San Diego, California, United States of America.
Anand GiddabasappaComparative Medicine, Pfizer Worldwide Research, Development & Medical, San Diego, California, United States of America.
Chang-Ning LiuComparative Medicine, Pfizer Worldwide Research, Development & Medical, Groton, Connecticut, United States of America.ORCID 0000-0002-2094-1401
Kristin MatthewsComparative Medicine, Pfizer Worldwide Research, Development & Medical, San Diego, California, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In oncology research, while xenograft tumor models are easily visualized and humane endpoints can be clearly defined, metastatic tumor models are often based on more subjective clinical observations as endpoints. This study aimed at identifying objective non-invasive criteria for predicting imminent distress and mortality in metastatic lung tumor-bearing mice. BALB/c and C57BL/6 mice were inoculated with CT26 or B16F10 cells, respectively. The mice were housed in Vium smart cages to continuously monitor and stream respiratory rate and locomotion for up to 28 days until scheduled euthanasia or humane endpoint criteria were met. Body weight and body temperature were measured during the study. On days 11, 14, 17 and 28, lungs of subsets of animals were microCT imaged in vivo to assess lung metastasis progression and then euthanized for lung microscopic evaluations. Beginning at day 21, most tumor-bearing animals developed increased respiratory rates followed by decreased locomotion 1-2 days later, compared with the baseline values. Increases in respiratory rate did not correlate to surface tumor nodule counts or lung weight. Body weight measurement did not show significant changes from days 14-28 in either tumor-bearing or control animals. We propose that increases in respiratory rate (1.3-1.5 X) can be used to provide an objective benchmark to signal the need for increased clinical observations or euthanasia. Adoption of this novel humane endpoint criterion would allow investigators time to collect tissue samples prior to spontaneous morbidity or death and significantly reduce the distress of mice in the terminal stages of these metastatic lung tumor models.

Indexed as

Lung NeoplasmsAnimalsBody WeightCell Line, TumorDisease Models, AnimalFemaleMiceMice, Inbred BALB CMice, Inbred C57BLRespiratory Rate

Identifiers

PMID34543354
PMCPMC8452061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.